C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice

• Main Authors: Daoqi Tang (Author), Hong Tian (Author), Jicheng Wu (Author), Jiaxiao Cheng (Author), Cheng Luo (Author), Wenbo Sai (Author), Xiaoda Song (Author), Xiangdong Gao (Author), Wenbing Yao (Author)
• Format: Book
• Published: Elsevier, 2018-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

PEG modification is a common clinical strategy for prolonging the half-life of therapeutic proteins or polypeptides. In a previous work, we have successfully synthesized PEG-modified Exendin-4 (PE) by conjugating a 20 kDa PEG to the C-terminal of Exendin-4. Then, we introduced an integrative charact...